Why activating mitochondrial genes doesn't cure Parkinson's disease

Research on Parkinson's disease has hit an unexpected barrier: activating the genes responsible for clearing damaged mitochondria doesn't produce the functional recovery that laboratory models predicted. The problem lies in the fact that the PINK1/Parkin pathway requires functional continuity across multiple sequential steps—from damage recognition through lysosomal degradation—and under Parkinson's-relevant conditions, these steps become partially uncoupled. When a single stage fails, the entire cascade collapses, even if the initial step is successfully activated. This mitochondrial dysfunction additionally interacts with α-synuclein accumulation, lysosomal impairment, and neuroinflammation, forming a self-reinforcing pathological network that upstream signaling alone cannot resolve. For Spanish longevity-focused clinicians and biohackers, the implication is direct: future trials must measure whether mitophagy actually completes, not merely activates, and require more sophisticated models paired with patient stratification aligned to disease biology.